Current and historical daily PE Ratio for NLTX (
Neoleukin Therapeutics Inc
) from 2014 to Jun 08 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Neoleukin Therapeutics stock (NLTX) PE ratio as of Jun 08 2024 is 0.
More Details
Neoleukin Therapeutics Inc (NLTX) PE Ratio (TTM) Chart
Neoleukin Therapeutics Inc (NLTX) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1128
- 1
- 2
- 3
- 4
- 5
- 6
- 13
| Neoleukin Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-08 | At Loss | 2023-10-16 | At Loss |
| 2023-12-18 | At Loss | 2023-10-13 | At Loss |
| 2023-12-15 | At Loss | 2023-10-12 | At Loss |
| 2023-12-14 | At Loss | 2023-10-11 | At Loss |
| 2023-12-13 | At Loss | 2023-10-10 | At Loss |
| 2023-12-12 | At Loss | 2023-10-09 | At Loss |
| 2023-12-11 | At Loss | 2023-10-06 | At Loss |
| 2023-12-08 | At Loss | 2023-10-05 | At Loss |
| 2023-12-07 | At Loss | 2023-10-04 | At Loss |
| 2023-12-06 | At Loss | 2023-10-03 | At Loss |
| 2023-12-05 | At Loss | 2023-10-02 | At Loss |
| 2023-12-04 | At Loss | 2023-09-29 | At Loss |
| 2023-12-01 | At Loss | 2023-09-28 | At Loss |
| 2023-11-30 | At Loss | 2023-09-27 | At Loss |
| 2023-11-29 | At Loss | 2023-09-26 | At Loss |
| 2023-11-28 | At Loss | 2023-09-25 | At Loss |
| 2023-11-27 | At Loss | 2023-09-22 | At Loss |
| 2023-11-24 | At Loss | 2023-09-21 | At Loss |
| 2023-11-22 | At Loss | 2023-09-20 | At Loss |
| 2023-11-21 | At Loss | 2023-09-19 | At Loss |
| 2023-11-20 | At Loss | 2023-09-18 | At Loss |
| 2023-11-17 | At Loss | 2023-09-15 | At Loss |
| 2023-11-16 | At Loss | 2023-09-14 | At Loss |
| 2023-11-15 | At Loss | 2023-09-13 | At Loss |
| 2023-11-14 | At Loss | 2023-09-12 | At Loss |
| 2023-11-13 | At Loss | 2023-09-11 | At Loss |
| 2023-11-10 | At Loss | 2023-09-08 | At Loss |
| 2023-11-09 | At Loss | 2023-09-07 | At Loss |
| 2023-11-08 | At Loss | 2023-09-06 | At Loss |
| 2023-11-07 | At Loss | 2023-09-05 | At Loss |
| 2023-11-06 | At Loss | 2023-09-01 | At Loss |
| 2023-11-03 | At Loss | 2023-08-31 | At Loss |
| 2023-11-02 | At Loss | 2023-08-30 | At Loss |
| 2023-11-01 | At Loss | 2023-08-29 | At Loss |
| 2023-10-31 | At Loss | 2023-08-28 | At Loss |
| 2023-10-30 | At Loss | 2023-08-25 | At Loss |
| 2023-10-27 | At Loss | 2023-08-24 | At Loss |
| 2023-10-26 | At Loss | 2023-08-23 | At Loss |
| 2023-10-25 | At Loss | 2023-08-22 | At Loss |
| 2023-10-24 | At Loss | 2023-08-21 | At Loss |
| 2023-10-23 | At Loss | 2023-08-18 | At Loss |
| 2023-10-20 | At Loss | 2023-08-17 | At Loss |
| 2023-10-19 | At Loss | 2023-08-16 | At Loss |
| 2023-10-18 | At Loss | 2023-08-15 | At Loss |
| 2023-10-17 | At Loss | 2023-08-14 | At Loss |
Neoleukin Therapeutics Inc (NLTX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Neoleukin Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US03842B1017
Description
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers